Anemia And Other Blood Disorder Drugs Market Report 2026

Anemia And Other Blood Disorder Drugs Market Overview

• Anemia And Other Blood Disorder Drugs market size has reached to $12.46 billion in 2025 • Expected to grow to $16.88 billion in 2030 at a compound annual growth rate (CAGR) of 6.5% • Growth Driver: Rising Demand For Personalized Medicine Drives Growth In The Anemia And Other Blood Disorder Drugs Market • Market Trend: Increasing Focus On Developing Novel Medications • North America was the largest region in 2025 and Middle East is the fastest growing region.

What Is Covered Under Anemia And Other Blood Disorder Drugs Market?

Anemia and Other Blood Disorder Drugs refer to the medications or drugs that are used to treat anemia and other blood disorder diseases. It refers to a blood condition that develops when a medication prompts the body's immune system to begin attacking its own red blood cells. Hemolysis, a process that causes red blood cells to degrade earlier than usual, is brought on by this. The main types of anemia and other blood disorder drugs are iron deficiency anemia, chronic kidney disease anemia, sickle cell anemia, and aplastic anemia. Iron deficiency anemia is a common kind of anemia in which the blood does not contain enough healthy red blood cells. The oxygen-carrying red blood cells transport oxygen to the body's cells. The different types of anemia include microcytic (Low MCV), normocytic (Normal MCV), and macrocytic (High MCV) and involve various routes of administration such as oral, and injectable. It is distributed through hospitals pharmacies, online pharmacies, and pharmacy.

What Is The Anemia And Other Blood Disorder Drugs Market Growth Forecast?

The anemia and other blood disorder drugs market size is expected to see strong growth in the next few years. It will grow to $16.88 billion in 2030 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to growth in gene therapy adoption, increasing aging population, rising awareness of blood disorders, expansion of specialty hematology clinics, improved diagnostic rates. Major trends in the forecast period include rising prevalence of chronic blood disorders, increasing use of injectable therapies, expansion of gene therapy for rare anemias, growing focus on personalized hematology treatments, improved access to essential blood disorder drugs.

Global Anemia And Other Blood Disorder Drugs Market Segmentation

1) By Type: Iron Deficiency Anemia, Chronic Kidney Disease Anemia, Sickle Cell Anemia, Aplastic Anemia 2) By Route of Administration: Oral, Injectable 3) By Distribution Channel: Hospitals Pharmacy, Online Pharmacy, Pharmacy Subsegments: 1) By Iron Deficiency Anemia: Oral Iron Supplements, Injectable Iron Supplements, Iron Fortified Foods 2) By Chronic Kidney Disease Anemia: Erythropoiesis-Stimulating Agents (ESAs), Iron Supplements, Blood Transfusion 3) By Sickle Cell Anemia: Hydroxyurea, Blood Transfusions, Gene Therapy, Pain Management Drugs 4) By Aplastic Anemia: Immunosuppressive Therapy, Stem Cell Transplantation, Erythropoiesis-Stimulating Agents (ESAs)

What Is The Driver Of The Anemia And Other Blood Disorder Drugs Market?

The rising demand for personalized medicine is expected to propel the growth of the anemia and other blood disorder drugs market going forward. Personalized medicine is a medical approach that uses an individual's genetic profile to guide prevention, diagnosis, and treatment decisions. The demand for personalized medicine is rising due to its ability to deliver more effective, targeted therapies that improve patient outcomes and long-term health. The anemia and other blood disorder drugs market supports personalized care by enabling individualized treatment plans that address specific genetic or molecular characteristics of blood disorders. For instance, in May 2024, according to the American Psychiatric Association, a US-based non-profit organization, 43% of adults report feeling more anxious than they did the year before, an increase from 37% in 2023 and 32% in 2022. Therefore, the rising demand for personalized medicine is driving the growth of the anemia and other blood disorder drugs industry.

Key Players In The Global Anemia And Other Blood Disorder Drugs Market

Major companies operating in the anemia and other blood disorder drugs market are Amgen Inc, GlaxoSmithKline plc, Akebia Therapeutics Inc., Bayer AG, Pfizer Inc, F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme Corp., Novartis AG, Global Blood Therapeutics Inc., Eli Lilly and Company, FibroGen Inc., bluebird bio Inc., Acceleron Pharma Inc., AMAG Pharmaceuticals Inc., Vifor Pharma Management Ltd., Sanofi S.A., AbbVie Inc., Johnson & Johnson, Daiichi Sankyo Company Limited, Pharmacosmos A/S, Emmaus Medical Inc., Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Merck & Co. Inc., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc., Grifols S.A.

Global Anemia And Other Blood Disorder Drugs Market Trends and Insights

Major companies operating in the anemia and other blood disorder drugs market are focusing on introducing novel medications to improve therapeutic outcomes, expand treatment options, and strengthen their competitive position. Novel medications refer to innovative pharmaceutical therapies that offer new mechanisms of action, superior efficacy, or improved safety profiles compared to existing treatments, addressing unmet needs in conditions such as anemia and myelodysplastic syndromes. For instance, in August 2023, Bristol-Myers Squibb Company, a US-based pharmaceutical company, received FDA approval for Reblozyl as the first-line treatment of anemia in adults with lower-risk myelodysplastic syndromes, marking the first therapy to demonstrate superiority over an erythropoiesis-stimulating agent in this setting, supported by Phase 3 COMMANDS trial data showing that nearly twice as many Reblozyl-treated patients achieved at least 12 weeks of transfusion independence with concurrent hemoglobin improvement compared to those receiving Epoetin alfa.

What Are Latest Mergers And Acquisitions In The Anemia And Other Blood Disorder Drugs Market?

In April 2023, Vertex Pharmaceuticals Inc., a US-based biotechnology company, expanded its long-standing partnership with CRISPR Therapeutics to advance exagamglogene autotemcel (exa-cel), a CRISPR/Cas9 gene-editing therapy for sickle cell disease and transfusion-dependent β-thalassemia; the partnership strengthens Vertex’s position in the anemia and blood-disorder therapeutics market by accelerating regulatory progress and supporting late-stage development of a potential one-time curative treatment, while enhancing CRISPR Therapeutics’ clinical and commercial impact by combining its gene-editing platform with Vertex’s development, regulatory, and commercialization capabilities. CRISPR Therapeutics is a Switzerland- and US-based biotechnology company specializing in CRISPR-based gene-editing therapies.

Regional Insights

North America was the largest region in the anemia and other blood disorder drugs market in 2025. Middle East is expected to be the fastest-growing region in the anemia and other blood disorder drugs market during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Anemia And Other Blood Disorder Drugs Market?

The anemia and other blood disorder drugs market consists of sales of folate analogues, multivitamin and mineral supplements, iron supplements, and erythropoiesis-stimulating agents. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Anemia And Other Blood Disorder Drugs Market Report 2026?

The anemia and other blood disorder drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the anemia and other blood disorder drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.